What is it used for?
STRENSIQ® is indicated for the treatment of patients with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP).STRENSIQ® is indicated for the treatment of patients with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP).
Read the primary sourceThis source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Product details
- Active ingredient
- asfotase alfaasfotase alfa
- Form and strength
- SOLUTION · 18 mg / 0.45 mL; SOLUTION · 28 mg / 0.7 mL; SOLUTION · 40 mg / 1 mL; SOLUTION · 80 mg / 0.8 mLSOLUTION · 18 mg / 0.45 mL; SOLUTION · 28 mg / 0.7 mL; SOLUTION · 40 mg / 1 mL; SOLUTION · 80 mg / 0.8 mL
- Manufacturer / applicant
- ALEXION PHARMACEUTICALS, INC.ALEXION PHARMACEUTICALS, INC.
STRENSIQ is a clear, slightly opalescent or opalescent, colorless to slightly yellow aqueous solution; few small translucent or white particles may be present. The product is available as: Injection: 18 mg/0.45 mL, 28 mg/0.7 mL, 40 mg/mL, or …STRENSIQ is a clear, slightly opalescent or opalescent, colorless to slightly yellow aqueous solution; few small translucent or white particles may be present. The product is available as: Injection: 18 mg/0.45 mL, 28 mg/0.7 mL, 40 mg/mL, or …
Safety and clinical review
Patients treated with enzyme replacement therapies have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Anaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration of therapy. Initiate STRENSIQ under the supervision of a healthcare provider with appropriate medical …Patients treated with enzyme replacement therapies have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Anaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration of therapy. Initiate STRENSIQ under the supervision of a healthcare provider with appropriate medical …
- Hypersensitivity Reactions Including AnaphylaxisHypersensitivity Reactions Including Anaphylaxis
- LipodystrophyLipodystrophy
- Ectopic CalcificationsEctopic Calcifications
- Possible Immune-Mediated Clinical EffectsPossible Immune-Mediated Clinical Effects
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Read the primary sourcePrepare your enquiry
Include the brand or generic name, strength, dosage form, requested quantity and country where care is needed. You can attach a prescription when you continue.
Questions patients ask
What is Strensiq used for?
STRENSIQ® is indicated for the treatment of patients with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP).STRENSIQ® is indicated for the treatment of patients with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP).
This source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Which formulation of Strensiq should I ask about?
SOLUTION · 18 mg / 0.45 mL; SOLUTION · 28 mg / 0.7 mL; SOLUTION · 40 mg / 1 mL; SOLUTION · 80 mg / 0.8 mLSOLUTION · 18 mg / 0.45 mL; SOLUTION · 28 mg / 0.7 mL; SOLUTION · 40 mg / 1 mL; SOLUTION · 80 mg / 0.8 mL
Read the primary sourceWhat determines the price of Strensiq?
A current quote depends on the exact presentation, quantity, provider and access arrangements. A catalogue entry is not a stock or delivery promise. Medical charges are paid to the provider, separately from coordination fees.
What should I check before using Strensiq?
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Sources and review scope
FDA prescribing informationThis source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.